Medical Policy and Coding Updates - February 2025
Summary
Premera's February 2025 update adds carpal tunnel release as a new surgical policy effective May 6, 2025, and changes IL-5 inhibitor and Dupixent asthma criteria, including the blood eosinophil count, which was lowered from 300 to 150 cells/mcL. It also moves Briumvi, Lemtrada, Ocrevus, Ocrevus Zunovo, Tyruko and Tysabri from the multiple sclerosis policy into a new Gene Therapies for Rare Diseases policy effective February 1, 2025, and removes site-of-service review from many infusion and biologic codes while keeping medical necessity and prior authorization review.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.